Rho names renowned neurologist Andrew Feigin, MD, as Chief Medical Officer
Rho names renowned neurologist Andrew Feigin, MD, as Chief Medical Officer. Dr. Feigin brings 30 years of experience to strengthen Rho’s clinical research program.
Neurology & Psychiatry
Unlocking sleep’s role in PTSD
Ben Vaughn, Rho’s Chief Strategist, Biostatistics & Protocol Design, supports Tonix Pharmaceutical’s analyses of how sleep disturbances impact posttraumatic stress disorder (PTSD). Their research sheds light on a novel treatment, TNX-102 SL, which targets sleep quality and emotional memory processing.
A Conversation about Parkinson’s Clinical Trials with Dr. Peter Schmidt and Dr. Mark Stacy
Dr. Peter Schmidt, PhD, and Dr. Mark Stacy, MD discuss participating in clinical trials for Parkinson’s. Dr. Schmidt, a Davis Phinney Foundation board member, is the Chief Scientific Officer for Rho, a company that supports clinical trial strategy, design, and operations and Dr. Stacy has been involved in Parkinson’s care and research for over thirty years.
‘Tis the Season: Shedding Light on Seasonal Affective Disorder
Seasonal affective disorder (SAD), also known as major depressive disorder with a seasonal pattern, is a condition of regularly recurring depressive episodes that most commonly occur in autumn and winter and remit during spring and summer. Despite the relatively high prevalence and morbidity of SAD, this disorder still often goes undiagnosed, in large part because health care professionals do not generally consider a potential seasonal pattern in a patient who presents with depression.
Overcoming the Complex Challenges in Schizophrenia Trials
Schizophrenia is a disabling, lifelong disease that is difficult to diagnose and treat due to its complexities and challenges. These same intricacies and complications are a critical part of clinical trial development that require a deep understanding of the disease and how to mitigate the anticipated challenges during trial design necessary to advance treatment without delaying study timelines. we discuss how to overcome three of the most complex challenges of any Schizophrenia trial:
Assessments and Scales. Raters and Site Management, and Recruitment and Retention.